Rheumatoid arthritis (RA) is a systemic autoimmune disease that results in a chronic and inflammatory disorder. Dynamic balance of helper T cells (Th) 1 and 17 and regulatory T cells (Treg) is broken in RA. Since there is no cure for RA at present, it is necessary to find a truly effective and convenient treatment. Several studies have intended to induce ergotopic regulation to treat autoimmune diseases. This study was undertaken to find potential ergotope peptides and investigate their effects in treating the animal model of RA and their underlying regulatory mechanisms. First, we selected functional ergotope peptides from 25 overlapping peptides derived from the interleukin 2 receptor (IL-2R) α chain, and then used these peptides to treat collagen-induced arthritis (CIA). We showed ergotope peptides as immunomodulatory factors with great benefits at the clinical and pathologic levels. This effect was associated with inhibition of type II collagen (CII)-specific proliferation and autoantibody production as well as induction of antiergotypic immune response, downregulation of both Th1 and Th17 cells and their related components, and emergence of Treg cells that had suppressive action on autoreactive T cells. We also proved that cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and IL-10 are two important mediators that are critical to Treg suppressive function. Inhibition of Th1 and Th17 in established CIA could be attributed to ergotope-induced Treg cells. Our findings reveal that ergotope peptides induce regulatory immune responses and restore immune tolerance, suggesting that treatment with ergotope peptides may be a novel approach to therapy for RA patients and has good application prospects, with cheap, effective, convenient, wide-spectrum features.
helper T cell (Th) 1 responses and the principal effector cytokine interferon (IFN)-γ mediate the synovial inflammatory cascade, synovial hyperplasia and joint destruction in arthritis (3) (4) (5) (6) . In 2005, Th17 was defined as a new subset of Th cells (7, 8) . Th17 cells are characterized by production of interleukin (IL)-17, which is elevated in RA patients and in the CIA mouse model, involving synovitis and articular cartilage damage (9) (10) (11) . In contrast, regulatory T cells (Treg), known as suppressor T cells, are a subpopulation of T cells that modulate the immune system and abrogate autoimmune disease by expressing coinhibitory molecules, such as cytotoxic T lymphocyteassociated antigen-4 (CTLA-4), or secreting antiinflammatory cytokines, such as IL- 10 (12,13) . In a steady state, Th1, Th17 and Treg may remain in dynamic Although the etiology and pathogenesis of RA remain unknown, immunological hyperreactivity caused by many T cells, mostly cluster of differentiation (CD) 4 and plasma cells, is generally considered to be an important contributor to its development. Both clinical and experimental evidence strongly suggest that iNTRODuCTiON Rheumatoid arthritis (RA) is a chronic inflammatory disease of polyarticular arthritis affecting approximately 1% of adults worldwide (1, 2) . It typically leads to deformity and destruction of the joints, as well as systemic disorders throughout the body.
Therapeutic Effect of Ergotope Peptides on Collagen-induced Arthritis by Downregulation of inflammatory and Th1/Th17
Responses and induction of Regulatory T Cells 
Ergotope Peptide Synthesis and Treatment
Twenty-five overlapping peptides and three control peptides containing 20 amino acids were synthesized according to the amino acid sequence of murine CD25 (IL-2Rα) and CD132 (IL-2Rγ).The sequences are as follows: peptide 1 (p1, aa 1-20) meprllmlgf lsltivpscr; peptide 2 (p2, aa 11-30) lsltivpscr aelclydppe; peptide 3 (p3, aa 21-40) aelclydppe vpnatfkals; peptide 4 (p4, aa 31-50) vpnatfkals ykngtilnce; peptide 5 (p5, aa 41-60) ykngtilnce ckrgfrrlke; peptide 6 (p6, aa 51-70) ckrgfrrlke lvymrclgns; peptide 7 (p7, aa 61-80) lvymrclgns wssncqctsn; peptide 8 (p8, aa 71-90) wssncqctsn shdksrkqvt; peptide 9 (p9, aa 81-100) shdksrkqvt aqlehqkeqq; peptide 10 (p10, aa 91-110) aqlehqkeqq tttdmqkptq; peptide 11 (p11, aa 101-120) tttdmqkptq smhqenltgh; peptide 12 (p12, aa 111-130) upregulated during the course of T cell activation, and ultimately it is presented to and induces antiergotypic regulators. Since expression of CD25 and hot shock protein (HSP) 60 are induced upon T cell activation, it was suggested that CD25 (interleukin-2 receptor α chain, IL-2Rα) and HSP60 might serve as the ergotopes (26) (27) (28) . HSP60, acting as ergotope, was found to control both the effector T cells and the regulatory HSP60-specific T cells that control them (28) .
The aim of this study was to screen the functional peptide(s) of the IL-2Rα chain, investigate the activities of the functional peptide(s) in an experimental model of RA and reveal the potential mechanisms. Administration of ergotope peptides showed great benefits at the clinical and pathologic levels. This effect was associated with inhibition of CII-specific proliferation and induction of antiergotypic immune response, downregulation of both Th1 and Th17 cells and their related components of the disease, and emergence of Treg cells that had suppressive actions on CII-specific T cells. This study has important implications for understanding and treating patients with RA with functional ergotope peptides that have good application prospects with cheap, effective, convenient, widespectrum therapy.
MATERiALS AND METHODS

Ethics Statement
The animal protocol used in this study was approved by the Institutional Review Board of Shanghai Jiao Tong University School of Medicine. All mice received humane care in compliance with the 2011 Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (29) .
Animals and Arthritis induction
Male DBA/1 mice 6 to 8 wks old were purchased from Shanghai SLAC Laboratory Animal Co. Ltd., and were housed in the animal care facility of Shanghai Jiao Tong University School of Medicine under pathogen-free conditions balance. When this delicate balance is broken, it can lead to autoimmune disease (14) . Decreased counts and functional defects of Treg in RA have been reported to be associated with a high tumor necrosis factor (TNF)-α level, which decreases forkhead box p3 (FOXP3) expression or defects in CTLA-4 expression (15) (16) (17) . Thus it is meaningful for clinical treatment and assessment to study Th subsets involved in RA as well as the balance of effector T cells and regulatory T cells in RA patients and CIA, a frequently used animal model of human RA.
Regarding the current therapy, nonsteroidal antiinflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) are mainly used to reduce acute inflammation, thereby decreasing pain and improving function. As biotherapy is developed, several approaches to immunotherapy are applied to prevent and/or treat RA. Due to their crucial roles in the pathogenesis of RA, biological agents targeting inflammatory cytokines or autoreactive T cells, including TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, T cell costimulatory blockers and T cell vaccines, have led to effective therapy for RA (18, 19) . A phase I study of T cell vaccination (attenuated autoimmune T cells) in 13 RA patients was first reported in 1993 (20) . Later, our study found that a potentially beneficial immunomodulatory response toward activated T cells in general, specifically against peptides derived from the IL-2Rα-chain (so-called antiergotypic T cells), was obtained by vaccinating RA patients with expanded, activated and irradiated autologous synovial T cells (21) .
Immunization with attenuated activated autoreactive T cells induces a response in syngeneic animals that can induce protection or recovery from autoimmune disease (22, 23) . This process has been termed T cell vaccination (TCV) (24) . TCV activates both antiidiotypic and antiergotypic T cells. These regulators provide a useful view of the physiology of T cell regulation of the immune response (25 There are two modes of peptide administration: pulse administration, which was giving 1000 μg peptide in 500 μl volume intraperitoneally 2 wks before first immunization for prevention or 1 wk post first immunization for treatment, and every-other-day administration, which was giving 200 μg peptide in 200 μl volume intraperitoneally five times, starting from the same time points, for prevention or treatment. Mice in the control group were injected in the same way with the same volume of sterile phosphate-buffered saline (PBS).
Assessment of Arthritis
Mice were evaluated by two independent blinded examiners every day according to the following clinical score assessment system: grade 0 = no swelling; 1 = mild, with definite redness and swelling of the ankle or wrist or apparent redness and swelling limited to individual digits, regardless of the number of affected digits; 2 = moderate redness and swelling of ankle or wrist; 3 = severe redness and swelling of the entire paw, including digits; and 4 = maximally inflamed limb with involvement of multiple joints. Each limb was scored, yielding a maximum possible score per animal of 16.
Histologic Analysis
For histologic analysis, mice were euthanized by cervical dislocation at about 45 d after first immunization. The paws from four to six animals were randomly collected by two independent experimenters, fixed in 4% buffered formaldehyde, decalcified in ethylene diaminetetraacetic acid, embedded in paraffin and cut into 4 μm sections, which were then stained with hematoxylin and eosin. Histopathological changes were evaluated by optical microscope. Specifically, we assessed cell infiltration, cartilage destruction and bone erosion.
Mononuclear Cell Preparation
Splenic MNC suspensions from mice were prepared by grinding through a nylon mesh. Erythrocytes were osmotically lysed. MNCs were suspended in RPMI 1640 (Gibco, Life Technologies) supplemented with 200 U/mL penicillin, 200 U/mL streptomycin, 55 μM β2-mercaptoethanol and 10% heat-inactivated fetal bovine serum. thymidine incorporation was counted with a liquid scintillation counter.
Flow Cytometric Analysis
Splenocytes from each group were isolated on d 14 post immunization. For intracellular IL-17 and IFN-γ staining, splenocytes were stimulated for 5 h with 50 ng/mL phorbol myristate 5′-TCTGGGGTCACATTGTTGGAA-3′; IL-17, forward 5′-CTCCAGAAGGCC CTCAGACTAC-3′ and reverse 5′-GGGT CTTCATTGCGGTGG-3′; signal transducers and activators of transcription (STAT)3, forward 5′-TGCCCATGGCTACCTGTT-3′ and reverse 5′-GAACCTCCTGGGCTTA GTCC-3′; RAR-related orphan receptor g t (RORg t), forward 5′-GGAGCTCTGCC AGAATGAGC-3′ and reverse 5′-CAAGG CTCGAAACAGCTCCAC-3′; FOXP3, forward 5′-GGCCCTTCTCCAGGACAGA-3′ and reverse 5′-GCTGATCATGGCTGGG TTGT-3′. Relative quantification of gene expression was performed using the ABI Prism 7900 sequence detection system. SYBR Green master mix (ABI) was used for real-time RT-PCR to detect the abundance of PCR products among samples. Thermocycler conditions comprised an initial holding at 50°C for 2 min, then 95°C for 10 min. This was followed by a two-step PCR program consisting of 95°C for 15 s and 60°C for 60 s for 35 cycles. Data were collected and quantitatively analyzed on an ABI Prism 7900 HT sequence detection system (ABI). The β-actin gene was used as an endogenous control to normalize the differences in the amount of total RNA in each sample. All quantities were expressed as -fold values relative to a calibrator.
Adoptive Transfer of Arthritis
DBA/1 mice were immunized with CII and CFA in the presence or absence of peptide treatment. After 14 d, total CD4 + T cells, CD4 + CD25-T cells and CD4 + CD25 + T cells derived from CIA or peptide-treated CIA mice were resuspended in PBS and transferred (2 × 10 7 cells combined from the mice in the same group) into naive DBA/1 through intravenous injection, and then the mice were immunized with CII on the same day. Arthritis development was observed in recipient mice, as described above.
Statistical Analysis
All values are expressed as the mean ± SD. Student t test was used to analyze the differences between the groups. One-way ANOVA was initially ELISA as described (30) . Chicken CII (1 μg/mL) was coated onto microtiter plates overnight at 4°C. After blocking with 1% bovine serum albumin in PBS, serially diluted serum samples were added and incubated for 1 h at room temperature. After washing, goat antimouse IgG, IgG1 and IgG2a coupled with horseradish peroxidase (eBioscience) were added and incubated for 1 h at 37°C. Following five washes, tetramethylbenzidine was added and stopped by 2N H 2 SO 4 . Absorbance was then measured at 450 nm on a microplate reader (BioRad, Hercules). A standard serum composed of a mixture of sera from arthritic mice was added to each plate in serial dilutions and a standard curve was constructed. The standard serum was defined as 1 unit, and the antibody titers of serum samples were determined by the standard curve.
RNA isolation
Total RNA was isolated from splenic MNCs (1 × 10 6 ) with CII (20μg/mL) stimulation for 1 d using an RNeasy Mini Kit (Qiagen). Genomic DNA was removed from total RNA prior to cDNA synthesis using an RNase-free DNase Set (Qiagen). First-strand cDNA synthesis was performed for each RNA sample using a Sensiscript RT Kit (Qiagen). Random hexamers were used to prime cDNA synthesis.
Real-Time Reverse TranscriptionPolymerase Chain Reaction (RT-PCR) Analysis of Gene Expression
Primer Express software (ABI) was used to design primers from published cDNA sequences. Basic local alignment search tool searches were conducted on the primer nucleotide sequences to ensure gene specificity. The primer sequences were as follows: β-actin, forward 5′-TTCAACACCCCAGCCATGT-3′ and reverse 5′-GTGGTACGACCAGAG GCATACA-3′; IFN-g, forward 5′-GA TGCATTCATGAGTATTGCCAAGT-3′ and reverse 5′-GTGGACCACTCGGATG AGCTC-3′; T-bet, forward 5′-GGTGTC TGGGAAGCTGAGAG-3′ and reverse acetate (Sigma-Aldrich), 500 ng/mL ionomycin (Sigma-Aldrich) and GolgiPlug (BD Pharmingen) at the recommended concentrations. Cells were stained with fluorescein isothiocyanate-conjugated anti-CD4, fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen), and then labeled with allophycocyanin (APC)-conjugated anti-IFN-γ (eBioscience) and phycoerethrin (PE)-conjugated anti-IL-17 (eBioscience). To analyze Treg, APC-conjugated anti-CD4 (eBioscience) and PE-conjugated anti-CD25 (eBioscience) were used for surface staining. Cells were fixed and made permeable for 60 min at 4°C using a Fixation and Permeabilization Buffer Set (eBioscience) and were stained with FITC-conjugated anti-FOXP3 (eBioscience) for 60 min at 4°C in permeabilization buffer. Cells were stained with APC-conjugated anti-CTLA-4 to cell surface molecule. For intracellular staining of CTLA-4, surface stained cells were fixed and permeabilized with a Cytofix/ Cytoperm buffer set (BD Pharmingen) and then stained with APC-conjugated anti-CTLA-4. Cells were analyzed on a FACSCalibur flow cytometer.
Cytokine Measurement
The levels of cytokines were determined by enzyme-linked immunosorbent assay (ELISA) using IFN-γ, IL-17, transforming growth factor (TGF)-β and IL-10 kits (eBioscience). Serum samples were collected from each group of mice at the peak of disease and also adoptive transfer mice. Mice were euthanized on d 14 post first immunization. Then 200 μl aliquots of splenic MNC suspensions (5 × 10 6 /mL) were added into 96-well round-bottom microtiter plates and stimulated with CII (20 μg/mL). After 48 h of incubation at 37°C in 5% CO 2 and humidified atmosphere, the supernatants were harvested. The cytokines in the supernatants as well as sera were detected according the ELISA kit instructions.
immunoassay of Serum Anti-Cii Antibody Level
The levels of anti-CII and total IgG, IgG1 and IgG2a were measured by we applied therapeutic treatment with every-other-day administration to investigate the potential mechanisms. Histopathologic analysis of joints showed that peptide treatment significantly abrogated the chronic inflammation of synovial tissue, pannus formation, cartilage destruction and bone erosion that are characteristic of CIA ( Figure 2C ). Individuals with rheumatoid arthritis have autoreactive antibodies in their blood targeting their own body tissues. High levels of circulating antibodies have a strong correlation with development of RA and CIA. Ergotope peptide treatment resulted in reduced serum levels of CII-specific IgG, particularly IgG2a antibodies ( Figure 2D) .
To find the possible mechanisms, we determined the proliferation of splenic MNCs isolated from the CIA group, the control peptide (C-P) treated group, the P5-6 treated group and the P14-16 treated group in response to CII in vitro. CIA mice under ergotope peptide treatment significantly inhibited expansions of CII-specific mononuclear splenocytes ( Figure 3A) . CD4 + T cells from each group were sorted by MACS and stimulated with CII-specific T cells (TCV), control peptide, were considered to be potential functional sites of IL-2Rα that could serve as immunoreactive ergotope peptides and were used in the later experiments.
Ergotope Peptide Treatment Ameliorated the Development of CiA
CIA is a mouse model induced by immunization with an emulsion of CFA and type II collagen that shares features of the human autoimmune disease rheumatoid arthritis (31) . In this study, we used the CIA model to examine the effects of ergotope peptides. Two different modes of administration, pulse and every-other-day administration, were utilized in the peptide-treated groups. P5-6 and P14-16 peptide treatment of CIA mice resulted in a progressive decrease in the severity of CIA as compared with untreated mice (CIA) and control peptide treated mice (Figures 2A and B) . There was no significant difference between CIA mice and control peptide-treated mice, but P5-6 and P14-16 peptides had a preventive effect (Figure 2A ) as well as a therapeutic effect ( Figure 2B) . Furthermore, every-other-day administration was more effective than pulse administration. Thus, performed to determine whether an overall statistically significant change existed before using the two-tailed paired or unpaired Student t test. A value of P < 0.05 was considered statistically significant.
RESuLTS
Ergotope Peptides with immune Regulation were Screened
In previous studies, we found that TCV vaccine could induce antiergotypic regulation in patients with RA and in mice with CIA (21) . To further investigate the functional sites of murine IL-2Rα, we synthesized the overlapping peptide derivatives based on the structural features of IL-2Rα to generate peptide libraries. ELISPOT analysis was used to detect the IL-10-secreting cells in the different peptide-stimulated CD4 + T cells that were isolated from the draining lymph nodes of TCV-treated mice. IL-10 spot-forming cells were significantly increased when cells were stimulated with peptide 5 (IL-2R41-60), peptide 6 (IL-2R51-70), peptide 14 (IL-2R131-150), peptide 15 (IL-2R141-160) and peptide 16 (IL-2R151-170) (Figure 1 ). These peptides functions were decreased in RA (32) . The intricate balance between Th17, Th1 and Treg cell function was central in understanding the immunological mechanisms of autoimmune diseases (33) . We therefore investigated the influence of peptide treatment on Th subsets. Flow cytometry analysis showed that the percentages of Th1 and Th17 cells were significantly decreased in ergotope peptide-treated mice on d 14, when P14-16-treated mice showed even much less Th1 (0.87 ± 0.12) (Figure 4A , top) and Th17 (3.17 ± 0.19) ( Figure 4A , bottom) compared with the P5-6-treated group (Th1: 2.05 ± 0.07; Th17: 6.23 ± 1.18). In the advanced stage of CIA, not Th1 but Th17 decreased in CIA mice with ergotope treatment (data not shown). Similarly, P14-16 treatment was more effective at impacting Th17 (data not shown). In addition, splenic MNCs from CIA mice produced slightly higher levels of IFN-γ and IL-17, which are inflammatory cytokines secreted by Th1 and Th17 cells, respectively ( Figure 4B ), and lower levels of TGF-β and IL-10 ( Figure 4D ), antiinflammatory cytokines secreted mainly by Treg. P14-16 treatment significantly enhanced IL-10 production from splenocytes stimulated with CII. After treatment with ergotope peptide, CD4 + CD25 + FOXP3 + T cells were induced ( Figure 4C ) as well as their releasing cytokines, especially IL-10 ( Figure 4D ). Downregulation of systemic inflammatory cytokines ( Figure 4B ) and induction of antiinflammatory mediators ( Figure 4D ) were observed in sera, accompanied by Th subset changes. Moreover, gene expression of the Th1-related cytokine IFN-γ and its transcriptional factor T-bet were decreased, as well as that of the Th17 cytokine IL-17 and its transcriptional factors, STAT3 and RORγt ( Figure 4E ). In contrast, FOXP3 mRNA was upregulated after ergotope peptide treatment ( Figure 4E ).
The immunosuppression Function of Treg Cells Resumed
Our results indicate that the number of Treg cells was increased in mice treated with ergotope peptides. It is important to that ergotope peptide treatment induced antiergotypic immune response in vivo.
Ergotope Peptides Restored the Balance of Th Subsets
It was reported that effector T cell subsets that include Th1 and Th17 cells were involved in the pathogenesis of RA, while Treg with immune suppression P5-6 and P14-16. Compared with CD4 + T cells from the CIA and C-P groups, CD4 + T cells from the ergotope peptide-treated group could recognize TCV and generated more IL-10-secreting cells ( Figure 3B ). Additionally, those CD4 + T cells also recognized peptides 5-6 and peptides 14-16, which triggered more IL-10 spot formations, suggesting commonly used drugs like DMARDs and NSAIDs, which alleviate current symptoms and prevent future destruction of the joints, immunotherapies targeting inflammatory components have recently been discovered and developed. Therapeutic approaches include not only specific cytokine inhibitors, but also a T cell vaccine.
TCV has been reported to be effective in several T cell-mediated autoimmune diseases, including experimental autoimmune encephalomyelitis and experimental arthritis (39) . Immunization with inactivated autoreactive T cells (TCV) can be used as a powerful means of activating antiidiotypic and antiergotypic T cells to regulate the autoreactive T cells potentially involved in autoimmune conditions (40) (41) (42) . Our previous study found that T cell vaccination led to induction of CD4 + Tregs and CD8 + cytotoxic T cells specific for T cell vaccine by production of antiinflammatory IL-10 and cytotoxic activity (21) . These CD4 + T cells may represent the so-called antiergotypic T cells seen in experimental animals vaccinated with activated T cells. Cohen and colleagues and other investigators have demonstrated that IL-2 receptor α-chain (CD25) acts as one of these potential ergotopes (26, 43) . Compared with those from health controls, peripheral CD4 + T cells from RA patients had lower CD25 peptide response, which was restored after treatment with TCV. Our findings demonstrate that T cell vaccination induces regulatory immune responses that are associated with improved clinical and laboratory variables in RA patients (21) . Therefore, it is meaningful to find the ergotope peptide(s) with immunological activity.
Since TCV can induce antiergotypic response in CIA mice in vivo, we screened 25 overlapping peptides of CD25 to stimulate CD4 + T cells derived from TCV-treated mice and measured IL-10-secreting cells by ELISPOT. A significant increase in IL-10-producing cells was detected in cells treated with peptides 5, 6, 14, 15 and 16 compared with three control peptides that were group showed more obvious suppressive dysfunction under a blockade of IL-10 and CTLA-4, suggesting that ergotope peptides may have restored Treg function by upregulating the expression of CTLA-4 and the secretion of IL-10.
Ergotope Peptide-Treated Treg Cells Have Suppressive Function In Vivo
To further confirm the therapeutic effect of ergotope peptides and the mechanism by which they upregulate the quantity and quality of Treg cells, we determined the in vivo functions of ergotope peptide-treated T cells using adoptive transfer models. On d 14 post adoptive transfer, clinical scores were assessed. Mice received CD4 + CD25 + T cells from ergotope peptide-treated CIA mice, which dramatically reduced the arthritis ( Figure 6A) . Moreover, the serum levels of IgG and IgG2a were decreased in the mice that were transferred with CD4 + CD25 + T cells from ergotope peptide-treated donors ( Figure 6B ). Meanwhile, their CII-specific T cell proliferation was apparently inhibited ( Figure 6C ). These results demonstrate that the efficacy of ergotope peptides ameliorates CIA by inhibition of CII antigen-specific T cell activation and proliferation. It was also observed that the inflammatory cytokines IFN-γ and IL-17 were decreased and the antiinflammatory cytokines TGF-β and IL-10 were increased in both sera and the supernatants of CII-stimulated splenocytes of the recipient mice transferred with CD4 + CD25 + T cells from ergotope peptidetreated CIA mice ( Figure 6D ). The mRNA expressions of Th1, Th17 and Treg related cytokines and transcription factors displayed similar trends ( Figure 6E ).
DiSCuSSiON
Rheumatoid arthritis, a form of inflammatory arthritis, is an autoimmune disease without effective and specific treatment. In addition to its complicated risk factors, the pathogenesis of RA is not entirely clear, making it difficult to develop new drugs with therapeutic value and fewer side effects. Besides better understand the functions of Treg. CTLA-4 is a member of the immunoglobulin superfamily, which is expressed on the surface of T cells and transmits an inhibitory signal to T cells through interaction with CD80/CD86, which are members of the B7 family (34, 35) . The costimulation blocking agent CTLA-4Ig was applied successfully for the treatment of RA, having not only a systemic effect, but potentially also a local one (36) . In peptide-treated CIA mice, we found that extracellular ( Figure 5A ) and intracellular ( Figure 5B ) expressions of CTLA-4 in CD4 + CD25 + T cells were augmented, especially in the P14-16-treated group. The immunosuppressive function of CD4 + CD25 + regulatory T cells (Treg) from the group treated with ergotope peptides was significantly increased when we cocultured them with CD4 + CD25-effect T cells (Teff). Proliferation of Teff was conspicuously inhibited by Treg cells in the mice treated with ergotope peptides. As the proportion of Treg in the cultures increased, the extent of Teff proliferation decreased ( Figure 5C ). Moreover, Treg cells from the CIA and C-P treated groups had less ability to inhibit proliferation of Teff, suggesting an impaired function of Treg cells in CIA mice. Intriguingly, treatment with ergotope peptides restored the impaired suppressive function of Treg to some extent.
Treg cells are thought to suppress target cells by three mechanisms: cell-cell contact, local secretion of inhibitory cytokines and local competition for growth factors (37, 38) , in which CTLA-4 and IL-10 play important roles. We wanted to find out whether ergotope treatment restored Treg function through CTLA-4 and IL-10 pathways. As shown in Figure 5D , we blocked these two pathways using CTLA-4 and IL-10 function-blocking antibodies in the coculture system of Teff and Treg at a ratio of 5:1 and measured the proliferation response by H 3 -TdR. Blocked with IL-10 and CTLA-4 antibodies, Treg suppression was reduced in each group ( Figure 5D ). Compared to the CIA and C-P treated groups, the ergotope peptide-treated 
CONCLuSiON
In summary, this study identified ergotope peptides as an immunomodulatory factor with the capacity to reduce the inflammatory response in vivo at both gene and protein levels and to restore immune tolerance. This study provides clues to the development and progression of RA. Although our findings provide evidence that ergotope peptides may be a novel preventive and therapeutic approach to the treatment of RA and may be prior to TCV, whose in vitro amplification is relatively expensive and time-consuming and requires manpower and material resources, further studies are warranted to elucidate potential mechanisms as well as dosage and administration, and to define safe and effective clinical strategies. Moreover, the polymorphism of human major histocompatibility (MHC) genes is so great that in a mixed population there are not two individuals with exactly the same set of MHC genes and molecules, with the exception of identical twins; hence it is necessary to screen functional peptides under the background of RA-associated MHC. To explore the unrevealed problems, our next step will be to focus on the in vitro effects of ergotope peptides on RA patients. of transcription factor FOXP3 and secreted inhibitory cytokine IL-10 (21). Furthermore, these CD4 + IL-10-producing Treg cells induced by TCV were found to react specifically with peptides derived from IL-2 receptor α-chain, indicating that ergotope peptide treatment can induce Treg directly. The efficiency of inhibition in established arthritis by ergotope peptides and ergotope peptide-induced Treg cells could be explained by the fact that in addition to expanding the CD4 + CD25 + FOXP3 + Treg population, ergotope peptides also induced an efficient Treg population, in terms of both cytokine production and suppressive activity. The ergotope peptide-induced Treg cells secreted high levels of IL-10, but not TGF-β, and they were very strong suppressors of CD4 + CD25-effector T cell proliferation. Ergotope peptide treatment increased the surface and intracellular expression of CTLA-4, a costimulatory molecule that negatively regulates T cell activation, in CD4 + CD25 + Treg rather than in CD4 + CD25-T cells (46) . CTLA-4 is constitutively expressed by CD4 + CD25 + FOXP3 + Treg and blockade of CTLA-4 interferes with Treg function (47) . CTLA-4-deficient Treg failed to inhibit cytokine production associated with homeostatic expansion and was unable to prevent colitis (47, 48) . Our results suggest that the upregulation of CTLA-4 may contribute to the suppressive function of Treg cells.
To further study the potential pathway through which restored Treg cells act after ergotope peptide treatment, anti-CTLA-4 and anti-IL-10 antibodies were used separately or added together in the Treg/ Teff system. The suppressive function abrogated when the blocking antibodies were added. The application of combined antibodies impaired mostly Treg suppressive ability, which was obvious in Treg from ergotope peptide-treated mice with CIA. These results verified that CTLA-4 and IL-10 are two important mediators that are critical to Treg suppressive function.
Moreover, we also checked the in vivo function of ergotope peptide-induced randomly intercepted according to CD132 (IL-2Rγ). These IL-10 + CD4 + T cells may be ergotope-induced Treg cells. Selected functional ergotope peptides had both preventive and therapeutic effects in mice with CIA in vivo, reducing the frequency of arthritis, ameliorating symptoms and preventing joint damage. In addition, ergotope peptide treatment reduced autoantibody production in mice with CIA, in which CII-specific T cell proliferation was inhibited and IL-10-producing CD4 + T cells were induced, suggesting that ergotope peptides induced an antiergotypic immune response in CIA.
Since the mechanisms of these phenomena are incompletely understood, we investigated immunoregulation in ergotope peptide administration during CIA. It is widely known that effective immunological homeostasis relies on a continual balance among a number of factors, including helper T cell activation and regulatory T cell suppression. When homeostasis is disrupted, the host becomes susceptible to autoimmunity, in which autoreactive T cells contribute to the pathogenesis. Our further in vivo experiments demonstrated that ergotope peptide treatment had an impact on Th1 and Th17 cells. Downregulation of Th1 and Th17 cells was observed in ergotope peptide-treated mice, especially in the P14-16 group. The transcriptional factor of Th1 cells, T-bet and Th17, as well as STAT3 and RORγt was decreased, as well as the levels of cytokines IFN-γ and IL-17. The inhibition of Th1 and Th17 in established CIA could be attributed to ergotope-induced Treg cells.
Regulatory T cells play a pivotal role in the maintenance of tolerance as well as the control of immune activation by expressing the negative regulatory molecule CTLA-4 or secreting cytokines such as IL-10. The lineage-specific transcription factor FOXP3 is essential in Treg cell biology (13, 44) . Defects in CD4 + CD25 + Treg have been reported in RA (15, 45) . After TCV treatment, RA patients showed augmentation of CD4 + CD25 + Treg cells, which expressed a high level
